Lipigo F 5mg Tablet
10 Tablet(s) in StripMRP ₹98.80
₹69.16
30% OFF
Made by
MERCK LIMITED
Dosage
TABLET
Expiry
Product Summary
| Salt Content | Rosuvastatin(5.0 Mg)+Fenofibrate(160.0 Mg) |
| Uses | High cholesterol |
| Therapy | Hypolipidemic drugs |
| Side effects | Nausea, vomiting, headache, constipation, headache, gases, muscle pain, stomach pain |
Assurance
available
Regulated
Medical Description
Uses
Contraindications
- If you are allergic to Rosuvastatin and/or Fenofibrate.
- If you are suffering from severe liver disease, increased liver enzymes.
- If you are suffering from severe kidney diseases.
- If you have repeated or unexplained muscle aches or pains.
- If you take a drug called ciclosporin (used after organ transplants).
- If you have gall bladder disease.
- If you have an inflammation of the pancreas.
Side effects
- Stomach pain
- Diarrhoea
- Nausea
- Dizziness
- Gas
- Vomiting
- Headache
- Muscle pain
- Tiredness
Precautions and Warnings
Pregnancy
Breast Feeding
Driving
Alcohol
Other General Warnings
- You are pregnant, breastfeeding or are planning to get pregnant.
- You are suffering from kidney or liver disorders or are above 70 years of age.
- You are suffering from diabetes mellitus, as this medicine may increase blood sugar levels.
- You are suffering from or have ever suffered from gall bladder stones (cholelithiasis) or any gall bladder disease (as this medicine increases the risk of the formation of gall bladder stones).
- You have or ever had or are experiencing unexplained muscle aches or pains and/or have a family history of muscle disorder.
- You have a thyroid disorder or lung related disorder.
- You consume large amount of alcohol or drink too often.
- It is recommended that you have your liver functioning tests and kidney functioning test done at regular intervals.
Directions for Use
- Take Lipigo F Tablet as directed by your doctor with meals
- Swallow this Tablet as a whole with a glass of water.
Dosage
Overdose
Missed a Dose
Mode of Action
How Does It Work?
Interactions
Interactions with other medicines
- Using Lipigo F Tablet increases the risk of bleeding when used along with blood thinners like warfarin.
- Concomitant use of Lipigo F Tablet along with medicines that reduce the activity of the immune system (ciclosporin) may lead to kidney damage.
- When Lipigo F Tablet is taken along with medicines used to lower cholesterol (statins, gemfibrozil, fenofibrate, etc.) there is an increased chance of the development of muscle disorder.
- Oestrogen containing oral contraceptives may interfere with the working fenofibrate, the active ingredient in the Lipigo F Tablet, hence the use of oral contraceptives should be done with caution along with the Lipigo F Tablet.
- Concomitant use of medicines used to treat bacterial infections (fusidic acid) should be avoided as there is an increased risk of the development of muscle disorders.
- When medicines used to neutralise stomach acid (antacids) are taken along with Lipigo F Tablet they tend to decrease the concentration of rosuvastatin (the active ingredient in the Lipigo F Tablet) in the blood which may affect the efficacy of the medicine.
- Antiviral medicines like ritonavir are said to delay the elimination of rosuvastatin from the system, increasing its exposure to the system, concomitant use should be done carefully.
Frequently Asked Questions (FAQs)
Articles
View AllChronic Condition Articles
View AllDid you find this helpful?
Explore More at Pharmeasy
Manufacturer Details
Brand:LIPIGO F
Vendor Details
Fulfillment Information: Lipigo F 5mg Tablet will be delivered by a licensed retail pharmacy nearest to your location. Order acceptance and fulfillment are dependent upon the verification of your doctor's valid prescription (where applicable) and the current stock of this medicine.
References:
- CDSCO [Internet]. Cdscoonline.gov.in. 2022 [cited 16 Oct 2025]
- ROSTAR F (rosuvastatin + fenofibrate) — Torrent Pharmaceuticals [Internet]. Torrentpharma.com. 2024 [cited 7 October 2025].
- Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia - PubMedDurrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract. [cited 24 Jan 2025]
- A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy - PMCStrain JD, Farver DK, Clem JR. A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy. Clin Pharmacol. [cited 24 Jan 2025]
- National Center for Biotechnology Information (2025). PubChem Compound Summary for CID 446157, Rosuvastatin.[cited 24 Jan 2025]
- ScienceDirect. Rosuvastatin [Internet]. Accessed on: 24 JaScienceDirect. Rosuvastatin [Internet]. [cited 24 Jan 2025]..
In Case of Any Issues Contact Us
Email Id:care@pharmeasy.in
Phone Number:7666100300
Address:D-37/1, Opp. Sandoz, TTC Industrial Area, MIDC Industrial Area, Turbhe, Navi Mumbai, Maharashtra 400703
Disclaimer
The information provided herein is supplied to the best of our abilities to make it accurate and reliable as it is published after a review by a team of professionals. This information is solely intended to provide a general overview on the product and must be used for informational purposes only. You should not use the information provided herein to diagnose, prevent, or cure a health problem. Nothing contained on this page is intended to create a doctor-patient relationship, replace or be a substitute for a registered medical practitioner's medical treatment/advice or consultation. The absence of any information or warning to any medicine shall not be considered and assumed as an implied assurance. We highly recommend that you consult your registered medical practitioner for all queries or doubts related to your medical condition. You hereby agree that you shall not make any health or medical-related decision based in whole or in part on anything contained in the Site. Please click here for detailed T&C.



















